Top Page
333D Limited
(Sydney:T3D)
333D Limited (T3D) vs. iShares MSCI Australia ETF (EWA)
333D Limited Business Overview & Revenue Model
333D Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.00M | 1.01M | 190.31K | 23.95K | 63.68K | 114.97K |
| Gross Profit | 396.34K | 403.08K | 181.29K | -146.37K | -209.88K | -24.78K |
| EBITDA | 0.00 | 144.81K | -600.60K | -836.10K | -1.22M | -488.88K |
| Net Income | 143.78K | 143.78K | -506.61K | -724.97K | -1.24M | -338.79K |
Balance Sheet | ||||||
| Total Assets | 641.11K | 641.11K | 24.68K | 89.29K | 441.52K | 132.40K |
| Cash, Cash Equivalents and Short-Term Investments | 75.27K | 75.27K | 4.58K | 65.05K | 415.73K | 99.21K |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 300.00K |
| Total Liabilities | 686.08K | 686.08K | 553.85K | 505.88K | 365.68K | 678.88K |
| Stockholders Equity | -44.96K | -44.96K | -529.17K | -416.60K | 75.84K | -546.47K |
Cash Flow | ||||||
| Free Cash Flow | 70.68K | 70.68K | -60.46K | -350.69K | -195.78K | 90.04K |
| Operating Cash Flow | 70.68K | 70.68K | -60.46K | -350.69K | -195.78K | 90.04K |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 512.30K | 0.00 |
333D Limited Peers Comparison
333D Limited Corporate Events
333D Limited has announced a change in the director’s interest, specifically involving Dr. Richard Petty, who has acquired 1,000,000 performance rights as part of the company’s Long Term Incentive Plan. This acquisition was made without cash consideration, indicating a strategic move to align the director’s interests with the company’s long-term goals, potentially impacting the company’s governance and stakeholder confidence.
333D Limited has announced a change in the director’s interest, specifically involving Dr. Nigel Finch. The change involves the acquisition of 750,000 performance rights by Saki Partners (Services) Pty Ltd, a company controlled by Dr. Finch, as part of the company’s Long Term Incentive Plan. This move increases the total performance rights held by Saki Partners to 2,250,000, reflecting the company’s strategy to incentivize its leadership.
333D Limited has announced its Annual General Meeting (AGM) scheduled for November 28, 2025, to be held virtually. The company is inviting shareholders to submit questions related to the company’s operations and audit report, with a deadline for submissions set for November 26, 2025. Shareholders are encouraged to participate in the meeting and can vote either in person or by proxy, with specific guidelines provided for proxy voting.
333D Limited has announced the quotation of 2,666,666 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code T3D, effective October 20, 2025. This move is part of the company’s strategy to enhance its market presence and liquidity, potentially impacting its operations and stakeholders by increasing access to capital and expanding its investor base.
333D Limited has announced an update regarding its proposed issue of securities, specifically extending the closing date of its cleansing offer. This extension is part of a strategic move to ensure compliance with ASX Listing Rules and facilitate the quotation of securities, potentially impacting the company’s market operations and offering stakeholders more time to engage with the offer.
333D Limited announced that its 2025 Annual General Meeting will be held virtually on November 28, 2025. The company also confirmed the vesting of 2,666,666 Performance Rights for its directors, following the achievement of market capitalization milestones. Additionally, the closing date for its cleansing offer has been extended to December 19, 2025, allowing more time for participation.
333D Limited, a company involved in the capital raising sector, has announced that it has ceased to be a substantial holder in its own shares following the release of 10 million ordinary shares from voluntary escrow. This change occurred after the company lodged a cleansing prospectus with ASIC, which allowed for the removal of secondary trading restrictions on the shares. The release of these shares signifies a shift in the company’s relevant interest, impacting its operations and potentially influencing market perceptions.
333D Limited reported a successful quarter ending September 2025, with a 15.69% increase in cash receipts from its digital asset management services, particularly in the healthcare sector. The company raised $1 million through a placement to sophisticated investors and invested in a pilot collaboration with BioScan 360 to expand its services in the preventative healthcare market. Additionally, 333D Limited has acquired Bitcoin as part of its strategic treasury management and plans to expand its blockchain-based services nationally.
333D Limited has announced a proposed issue of securities, with a total of 100 fully paid ordinary shares to be issued under the ASX security code T3D. The proposed issue date for these securities is set for October 21, 2025. This announcement reflects the company’s ongoing efforts to manage its capital structure and potentially enhance its market presence through strategic placements.
333D Limited has released a prospectus for an offer of up to 100 new shares at an issue price of $0.10 per share. The prospectus aims to remove trading restrictions on shares issued before the closing date and is intended for a specific group of investors, not the general public. The investment is considered highly speculative, and potential investors are advised to conduct due diligence and consult with professional advisers. The offer is only available electronically within Australia, and applications must be submitted with the prospectus.